2019 Outlook: Drug Prices, Obamacare in Lawmakers’ Sights - Bloomberg Law

Michael Strazzella, Federal Government Relations practice group leader, comments on potential changes in the healthcare industry under new Congress and Senate leadership in 2019.

The Energy and Commerce Committee will take a role in enhanced scrutiny of high drug prices and the Trump administration’s changes to Obamacare because Pallone recognizes the Oversight Committee will be busy with other investigations, Mike Strazzella, leader of the federal government relations department at Buchanan, Ingersoll & Rooney, said in an interview.

Read more in Bloomberg Law's article "2019 Outlook: Drug Prices, Obamacare in Lawmakers' Sights."